Softwr

Research · head to head

Form Bio vs Seven Bridges

Form Bio logo

Form Bio

Research

Computational platform for cell and gene therapy design and manufacturability

From
On request
Rated
-
Seven Bridges logo

Seven Bridges

Research

Cloud bioinformatics platform and trusted research environment, sold by Velsera

From
On request
Rated
-

The short version

  • Each has a real cost: Form Bio the company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.; Seven Bridges the parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
  • They diverge on capability: Form Bio covers FormManufacturing, Seven Bridges covers Trusted research environment.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Form Bio and Seven Bridges actually diverge.

Attributes where Form Bio and Seven Bridges differ
AttributeForm BioSeven Bridges
PlatformsWeb, CloudWeb, API, Cloud

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Form Bio

  • FormManufacturing
  • Payload design optimisation
  • Genome integrity analysis
  • Manufacturability prediction
  • In silico workflows
  • Scale-up monitoring
  • Cell and gene therapy focus

Only in Seven Bridges

  • Trusted research environment
  • Cloud-agnostic
  • CWL pipelines
  • Compliance certifications
  • Cost prediction
  • Public data commons
  • Tool library

Both cover

  • Collaboration

What people use each for

The jobs each tool is most often brought in to do.

Form Bio

  • A gene therapy developer discovering manufacturability problems with an AAV construct late in process development and wanting to move that analysis earliernot Seven Bridges
  • A biotech comparing several candidate payload designs in silico before committing to expensive production runsnot Seven Bridges
  • A CDMO characterising what a client construct actually produces against what was specifiednot Seven Bridges
  • A programme team needing genome integrity evidence to support regulatory conversations about product consistencynot Seven Bridges

Seven Bridges

  • A cancer genomics group analysing controlled-access dbGaP data that cannot be moved to local infrastructurenot Form Bio
  • A federal or federally funded programme that needs FedRAMP Moderate authorisation for its analysis environmentnot Form Bio
  • A multi-institution consortium sharing pipelines and results under defined access controls rather than by emailing filesnot Form Bio
  • A diagnostics developer building reproducible CWL pipelines that must stand up to later regulatory reviewnot Form Bio

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Form Bio

  • The company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.
  • The current offering launched AAV-focused, so developers working in lentiviral, mRNA or cell therapy modalities are outside the scope the platform was built and validated for.
  • No pricing is published and engagements are scoped per programme, which makes it impossible to size the commitment before entering a sales process.
  • This is a young venture-funded company whose analyses feed regulatory-facing decisions, so continuity of the vendor over a multi-year development programme is a genuine diligence question rather than a formality.
  • Predictive manufacturability models need real production data to be trustworthy, and the value depends on how much of that a young vendor has accumulated, which is difficult for a buyer to verify independently.

Seven Bridges

  • The parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
  • Pricing is not published and splits into a platform subscription plus consumption-based cloud compute, so a heavy analysis quarter produces a bill that headcount-based budgeting does not anticipate.
  • The analysis capability itself has credible open source equivalents in Nextflow and Cromwell on raw cloud, so you are principally paying for compliance and governance rather than for the science.
  • Pipelines are built around Common Workflow Language, which is a real learning curve and a portability commitment for teams whose existing work is in other workflow languages.
  • Cloud storage of large genomic datasets accrues continuously whether or not you are analysing, and egress charges apply when moving results out, both of which are outside the subscription line.

Pricing, plan by plan

Form Bio

On request
  • FormManufacturing$undefined/year
    • Pricing only through a sales process
    • Scoped per therapeutic programme rather than per seat
    • AAV-focused offering at launch

Seven Bridges

On request
  • Seven Bridges Platform$undefined/year
    • Platform subscription quoted through Velsera sales
    • Cloud compute and storage charged on consumption on top of the subscription
    • Cost predictor tools provided to estimate analysis spend in advance

Which should you pick?

Choose Form Bio if

  • You need formmanufacturing.
  • You work on Web, Cloud.
  • You also want payload design optimisation.

Choose Seven Bridges if

  • You need trusted research environment.
  • You work on Web, API, Cloud.
  • You also want cloud-agnostic.

Questions people ask

Is Form Bio or Seven Bridges better?
Neither clearly leads. Form Bio starts at On request and Seven Bridges at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Form Bio or Seven Bridges?
Form Bio starts at On request and Seven Bridges at On request.
Does Form Bio or Seven Bridges run on more platforms?
Form Bio runs on Web, Cloud. Seven Bridges runs on Web, API, Cloud.
What is Form Bio best used for?
Form Bio is most often used for a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier, a biotech comparing several candidate payload designs in silico before committing to expensive production runs, a cdmo characterising what a client construct actually produces against what was specified, a programme team needing genome integrity evidence to support regulatory conversations about product consistency. Of those, a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier and a biotech comparing several candidate payload designs in silico before committing to expensive production runs are not what Seven Bridges is typically brought in for.
What can Form Bio do that Seven Bridges cannot?
Form Bio covers FormManufacturing, Payload design optimisation, Genome integrity analysis, Manufacturability prediction. Seven Bridges covers Trusted research environment, Cloud-agnostic, CWL pipelines, Compliance certifications. Both handle Collaboration.

Answered from the vendors’ own pages

Form Bio: What does Form Bio sell now?

FormManufacturing, launched in 2026, an AAV-focused platform for predicting, optimising and monitoring manufacturability of genetic medicines from construct design through scale-up.

Seven Bridges: Is Seven Bridges still sold?

Yes. It is sold by Velsera, formed in 2023 when Summa Equity merged Seven Bridges with Pierian and UgenTec. The Seven Bridges name was retained for the platform.

Form Bio: Is it still a general bioinformatics platform?

No. It has narrowed from broad computational life sciences tooling to cell and gene therapy, and within that to AAV.

Seven Bridges: What compliance does it hold?

FedRAMP Moderate, SOC 2, HIPAA, GDPR, dbGaP and ISO 27001, 27017, 27018 and 27701, which is the usual reason institutions choose it over building on raw cloud.

Form Bio: Where did the company come from?

It spun out of Colossal Biosciences in 2022.

Seven Bridges: How is it priced?

Not published. Expect a platform subscription plus consumption charges for cloud compute and storage.

Form Bio: Is pricing published?

No. Engagements are scoped per programme through a sales process.

Seven Bridges: Do I have to use a specific cloud?

No. The platform is cloud-agnostic and designed to bring analysis to where the data already resides.

Share

Related pages

Other head to heads